Department Winter Seminar Program 2020

＊発表時間は質疑応答も含め 1 人 15 分を目安として下さい。

12 月 21 日（月） Dec 21, Mon 9：30 ～ 17：15

Ⅰ Cell therapy for cancer immunity

【 9：30～10：30 Chairperson／K. Murata 村田 憲治 】

1. Development of a comprehensive analytical platform for the identification of TCR-antigen pairs toward adoptive T cell therapy. K. Murata 村田 憲治

2. PVT1 TCR-T cell therapy for sarcoma S. Hamada 濱田 修人

3. The chimeric antigen receptor T (CAR-T) therapy specific for the heat shock protein DNAJB8-derived peptide Y. Watanabe 渡部 裕人

Ⅱ Translational immunology 1

【 10：30～11：30 Chairperson／T. Kubo 久保 輝文 】

4. Identification of a spliced peptide as a CD8+ T-cell epitope using mass spectrometry-based HLA-ligandome analysis K. Kato 加藤 宏治

5. Cisplatin upregulates PD-L1 expression and inhibits cytotoxic T lymphocyte activity in oral squamous cell carcinoma. T. Sasaya 笹谷 聖

6. Roles of MHC class I antigen processing in ICI response against lung cancer.
K. Moniwa 茂庭 慶悟

7. Abscopal effect following nivolumab induction in a patient with metastatic renal cell carcinoma−unique pathological features of the primary specimen: A case report
K. Hori 堀 寛太

Lunch Time **【 11：30～12：30 】**

Ⅲ Translational immunology 2

【 12：30～13：45 Chairperson／T. Tsukahara 塚原 智英 】

8. Cellular mechanisms for endothelial fenestrae formation of the fenestrated capillaries
T. Suzuki　鈴木　健史

9. Immuotherapy for sarcoma　T. Tsukahara　塚原　智英

10. Bi-directional interaction between epithelial and immune cells in the setting of inflammation and cancer: what we can discuss from still pictures　T. Kubo　久保　輝文

11. ①Targetting ESR1 mutations in endocrine therapy-resistant breast cancer.
②Targeting human Endoplasmic oxidoreductin 1-Lα in novel therapy for triple negative breast cancer.
A. Wada　和田　朝香

12. CTL/naïve T-cell ratio at each regions of the metastatic lymph node in breast cancer patients.
H. Shima　島　宏彰

Ⅳ The biochemical mechanisms of antigen presentation

【 13：45～14：45　Chairperson／T. Kanaseki 金関 貴幸 】

13. Landscape of HLA-presented cancer antigens　T. Kanaseki　金関　貴幸

14. Direct identification of an immunodominant neoantigen from cancer tissue using a proteogenomic approach　S. Tokita　時田　芹奈

15. Characterization of $CD8^+$ T-cell responses to non-anchor-type HLA class I neoantigens with single amino-acid substitutions　T. Shinkawa　新川　知世

16. Pathophysiology of PVT1 and application to cancer therapy.　Y. Kikuchi　菊池　泰弘

Coffee Break **【 14：45～15：00 】**

Ⅴ Crosstalk of cancer immunity and tumor microenvironmen

【 15：00～16：00　Chairperson／Y. Hirohashi 廣橋 良彦 】

17. The biology of cancer stem cell and cancer immunity　Y. Hirohashi 廣橋　良彦

18. Investigation of cancer stem cell-specific cancer antigens in bladder cancer cell lines and Cancer associated fibroblast inhibit the function of cytotoxic T cell　S. Yamada　山田　修平

19. Cell fusion between macrophage and melanoma promote immune escape.　T. Minowa　箕輪　智幸

20. Dissemination modeling of ovarian cancer in mice and CTL induction.
R. Tsunematsu　常松　梨紗

Ⅵ Tumor-associated antigens

【 16：00～17：00　Chairperson／Y. Hirohashi 廣橋 良彦 】

21. Identification of HLA classII-presenting neoantigens in colon cancer by proteogenomics HLA ligandomeanalysis　S. Matsumoto　松本　哲

22. Human endogenous retrovirus (HERV) antigens are presented by HLA class I of renal cell carcinoma S. Kobayashi　S. Kobayashi　小林　進

23. Searching for neoantigens derived from driver mutation　K. Sasaki　佐々木　健太

24. The role of CD4+ T cells and MHC class ll Neoantigens specificity in tumor immunotherapy
M. Fusagawa　房川　美渚

Ⅶ Closing remarks

【 17：00～17：15 】

25. Immunopathology for precision immunotherapy of cancer　T. Torigoe　鳥越　俊彦